✨
AI Summary
- ENCORE trial shifted focus to patient-reported symptoms as primary endpoint.
- This reflects an FDA requirement and a change in trial design.
- Jakko van Ingen, MD, PhD, discusses amikacin liposome inhalation evaluation.